Using gene editing to improve targeted therapy for acute myeloid leukemia
Base-Edited Hematopoietic Stem and Progenitor Cells To Enable Safe Use Of Highly Potent CD33-Targeted Radioimmunotherapy
This study is looking at a new way to make treatments for acute myeloid leukemia safer and more effective by using gene editing to help your body better handle powerful therapies that target cancer cells, so you can get stronger doses with fewer side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10888198 on NIH RePORTER |
What this research studies
This research focuses on enhancing the safety and effectiveness of targeted therapies for acute myeloid leukemia (AML) by using gene editing techniques to modify hematopoietic stem and progenitor cells. The approach aims to enable the safe use of highly potent CD33-targeted radioimmunotherapy, which can deliver precise radiation to cancer cells while minimizing damage to normal cells. By utilizing CRISPR technology, the researchers hope to reduce the toxic side effects associated with current treatments, allowing for higher doses of therapy to be administered. Patients may be monitored for their response to this innovative treatment strategy over the course of the study.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia who are seeking advanced treatment options.
Not a fit: Patients with other types of leukemia or those who are not eligible for targeted therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective treatments for patients with acute myeloid leukemia.
How similar studies have performed: Previous research has shown promising results with similar targeted therapies, indicating potential for success in this novel approach.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Walter, Roland Bruno — Fred Hutchinson Cancer Center
- Study coordinator: Walter, Roland Bruno
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.